G-CSF safe, but antibiotics are more concerning in SCLC

May 10, 2017|Hematology and Oncology

FROM ELCC

The investigators speculated that the worse outcomes seen with prophylactic antibiotics could be related to selection bias or to chemotherapy dose reduction to suboptimal levels for those who received antibiotics.

“We are very reassured that there are no significant additional toxicities [with G-CSF] from radiation in the acute setting,” commented Sanjay Popat, FRCP, PhD, from the Royal Marsden Hospital in London, the invited discussant.

“However, we have no data as yet on the impact of G-CSF usage on febrile neutropenia, which is of course the fundamental that we’re aiming to improve in the hope that this will contribute to [lowering] costs,” he added.

The study was sponsored by the Christie Hospital National Health Service Foundation Trust, Cancer Research UK, EORTC, GECP, GFPC, and IFCT. Dr. Gomes reported no relevant disclosures. Dr. Popat reported consultation, honoraria, travel expenses, and institutional research from multiple entities.